Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Cediranib Filing Withdrawal: CHMP Had Two Major Issues

Executive Summary

European filing for ovarian cancer candidate cediranib was undone by differences in opinion between AstraZeneca and EMA's CHMP advisory committee in two key areas – the clinical benefit, and compliance with GCP.

You may also be interested in...



“Excellence In Execution” Is Key To AstraZeneca’s Bid To Be An Oncology Leader

Though AstraZeneca is in several ways playing catch up in the oncology space, a strategy built around speed, differentiation and carving out areas of leadership has the firm poised for transformation. Execs are particularly confident the company will become a dominant force as combinations become a larger part of cancer care, pulling from its immunotherapeutic and small molecule pipelines.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel